third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib)

DRUG2 trials

Sponsors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Fudan University

Conditions

Brain MetastasasesDisitamab VedotinERBB2 Gene DuplicationERBB2 Mutation-Related TumorsNSCLC (Advanced Non-small Cell Lung Cancer)Non Small Cell Lung Cancer

Phase 2

RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Not yet recruitingNCT06185400

Cancer Institute and Hospital, Chinese Academy of Medical SciencesDisitamab Vedotin, ERBB2 Gene Duplication, ERBB2 Mutation-Related Tumors +1

Start: 2024-02-01End: 2026-12-01Target: 108Updated: 2023-12-29

Unknown Phase

AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases

RecruitingNCT06604689

Fudan UniversityBrain Metastasases, NSCLC (Advanced Non-small Cell Lung Cancer)

Start: 2024-09-30End: 2025-10-01Target: 800Updated: 2024-11-12